ASLAN Pharmaceuticals Limited (ASLN)
NASDAQ: ASLN · IEX Real-Time Price · USD
0.600
-0.100 (-14.27%)
At close: Jul 18, 2024, 4:00 PM
0.560
-0.040 (-6.67%)
After-hours: Jul 18, 2024, 7:58 PM EDT

ASLAN Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2016
Revenue
12120003
Upgrade
Cost of Revenue
000000.41
Upgrade
Gross Profit
12120002.59
Upgrade
Selling, General & Admin
12.5913.249.8811.837.178.51
Upgrade
Research & Development
34.3342.53822.029.3116.59
Upgrade
Other Operating Expenses
0000023.07
Upgrade
Operating Expenses
46.9255.7447.8833.8516.4848.17
Upgrade
Operating Income
-34.92-43.74-47.88-33.85-16.48-45.58
Upgrade
Interest Expense / Income
3.924.333.681.861.250.9
Upgrade
Other Expense / Income
-3.95-3.98-0.27-4.12-0.760.18
Upgrade
Pretax Income
-34.9-44.09-51.28-31.59-16.97-46.66
Upgrade
Income Tax
0.130.130.1000.41
Upgrade
Net Income
-35.03-44.22-51.38-31.59-16.97-47.07
Upgrade
Shares Outstanding (Basic)
467411349326192162
Upgrade
Shares Outstanding (Diluted)
-411349326192162
Upgrade
Shares Change
25.91%17.93%7.07%69.43%18.37%8.45%
Upgrade
EPS (Basic)
-14.00-22.00-30.00-20.00-16.00-58.00
Upgrade
EPS (Diluted)
-14.00-22.00-30.00-20.00-16.00-58.00
Upgrade
Free Cash Flow
--43.33-35.99-34.04-15.05-25.51
Upgrade
Free Cash Flow Per Share
--21.07-20.64-20.91-15.66-31.41
Upgrade
Gross Margin
100.00%100.00%---86.42%
Upgrade
Operating Margin
-291.03%-364.46%----1519.30%
Upgrade
Profit Margin
-291.89%-368.50%----1568.85%
Upgrade
Free Cash Flow Margin
--361.09%----850.21%
Upgrade
EBITDA
--39.41-47.28-29.45-15.43-45.31
Upgrade
EBITDA Margin
--328.39%----1510.35%
Upgrade
Depreciation & Amortization
-0.350.330.280.30.45
Upgrade
EBIT
-30.98-39.76-47.61-29.73-15.72-45.76
Upgrade
EBIT Margin
-258.15%-331.29%----1525.20%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).